Product Description
The antisense oligonucleotide, PF-06473871, comprises a 20-nucleotide chain containing a phosphorothioate backbone and 2Õ-methoxyethyl modifications of the ribose units at the 3Õ and 5Õ ends, conferring resistance to nucleases and providing long residence in tissues. PF-06473871 targets CTGF expression and is delivered by intradermal injection to a surgical wound. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191237/)
Mechanisms of Action: CTGF Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Healthy Volunteers|Vision, Low|Other
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01753791 |
B5301002 | P1 |
Completed |
Healthy Volunteers |
2013-06-01 |
2019-03-19 |
Treatments |
|
NCT02205476 |
B5301012 | P2 |
Terminated |
Vision, Low |
2015-01-01 |
2019-03-20 |
Treatments |
|
2012-004355-37 |
2012-004355-37 | P2 |
Completed |
Unknown |
2014-10-17 |
2022-03-13 |
Treatments |
|
NCT01730339 |
B5301001 | P2 |
Completed |
Healthy Volunteers |
2014-10-01 |
2019-03-19 |
||
NCT01494922 |
EXC 001-206 | P2 |
Completed |
Other |
2013-09-10 |
2021-08-14 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|